Rallybio Avenzo Merger and $215M Financing | Lucid Diligence Brief
Rallybio and Avenzo’s reverse merger puts Nasdaq access, $215M financing and…
Pfizer Innovent Oncology Deal | Lucid Diligence Brief
Pfizer Innovent Oncology Deal tests China-originated ADC and multi-specific…
Lucid Diligence Brief: SELLAS REGAL AML Phase 3 Nears Final Analysis
Lucid Diligence Brief: SELLAS approaches REGAL AML final analysis for…
Lucid Diligence Brief: Cullinan Therapeutics Gains FDA Orphan Drug Designation for CLN-049
Lucid Diligence Brief: Cullinan Therapeutics Receives FDA Orphan Drug…
Lucid Diligence Brief: Plus Therapeutics and Ephemeral AI Partnership in CNS Oncology
Lucid Diligence Brief: Plus Therapeutics and Ephemeral AI partnership raises…
Lucid Diligence Brief: Helio Genomics and Syneos Health Deal
Lucid Diligence Brief: Helio Genomics and Syneos Health Deal to expand…
Lucid Diligence Brief: NeuroVision’s Durin Life Sciences acquisition
Lucid Diligence Brief: NeuroVision’s Durin Life Sciences acquisition…
Lucid Diligence Brief: Roche to acquire PathAI
Lucid Diligence Brief: Roche acquires PathAI for USD 1.05B to advance AI…
Lucid Diligence Brief: Huahui Health x BeOne Medicines $2 billion collaboration for cancer trispecific HH160
Lucid Diligence Brief: Huahui Health x BeOne Medicines $2 billion collaboration…
Lucid Diligence Brief: Chiesi to acquire KalVista Pharmaceuticals
Lucid Diligence Brief: Chiesi to acquire KalVista Pharmaceuticals Professional…
Lucid Diligence Brief: Teva to acquire Emalex Biosciences
Lucid Diligence Brief: Teva to acquire Emalex Biosciences Professional…
Lucid Diligence Brief: Coultreon Biopharma Raises $125M for SIK3 Inhibitor
Lucid Diligence Brief: Coultreon Biopharma Raises $125M for SIK3 Inhibitor…